Finance

Lists
LBRX:NASDAQ
LB Pharmaceuticals Inc
$44.94
-0.40%
(-0.18) 1D
$44.94
0.00% (0.00)
After hours
Closed: Nov 10, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LBRX...
Open
$44.38
High
$45.68
Low
$43.40
Mkt. cap
1.45B
Avg. vol.
421.31K
Volume
377.88K
52-wk high
$50.16
52-wk low
$14.32
EPS
-$2.98
Shares outstanding
32.36M
No. of employees
49
Open
$44.38
High
$45.68
Low
$43.40
Mkt. cap
1.45B
Avg. vol.
421.31K
Volume
377.88K
52-wk high
$50.16
52-wk low
$14.32
EPS
-$2.98
Shares outstanding
32.36M
No. of employees
49
News stories
From web sources and news partners
About LB Pharmaceuticals Inc
CEO-
Employees49
Founded2015
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Analyst ratings
Based on 10 analysts giving stock ratings to LBRX in the past 3 months
Strong buy
Buy
9
Hold
1
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for LBRX in the last 3 months.
Highest
Current $44.94
$80.00 (+78.02%)
Average
$60.70 (+35.07%)
Lowest
$35.00 (-22.12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$60.00
+33.5%
11/09/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Maintained
$65.00
+44.6%
11/06/2026
Malcolm Hoffman
BMO Capital
Buy
Maintained
$54.00
+20.2%
11/05/2026
Boobalan Pachaiyappan
Roth MKM
Hold
Reiterated
$35.00
-22.1%
11/06/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$78.00
+73.6%
11/06/2026
Delma Caiati
Guggenheim
Buy
Reiterated
$80.00
+78%
11/05/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$53.00
+17.9%
10/21/2026
Yatin Suneja
Guggenheim
Buy
Initiated
$80.00
+78%
10/05/2026
Unknown Analyst
Guggenheim
Buy
Initiated
$80.00
+78%
10/05/2026
Ami Fadia
Needham
Buy
Initiated
$68.00
+51.3%
10/02/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
$69.00
+53.5%
08/21/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
$45.00
+0.1%
08/12/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$46.00
+2.4%
07/21/2026
Rudy Li
Wolfe Research
Buy
Initiated
$45.00
+0.1%
07/07/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
7.98M
14.54M
43.05M
51.52M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.99M
7.46M
8.97M
10.98M
Operating expense
12.97M
22.00M
52.02M
62.50M
Total operating expenses
12.97M
22.00M
52.02M
62.50M
Operating income
-12.97M
-22.00M
-52.02M
-62.50M
Other non operating income
-401.00K
200.00K
-662.00K
-342.00K
EBT including unusual items
-11.47M
-19.05M
-51.60M
-59.07M
EBT excluding unusual items
-10.57M
-18.95M
-49.70M
-59.07M
Income tax expense
1.00K
-
-
-
Effective tax rate
-0.01%
-
-
-
Other operating expenses
-
-
-
-
Net income
-11.47M
-19.05M
-51.60M
-59.07M
Net profit margin
-
-
-
-
Earnings per share
-0.45
-0.67
-1.71
-1.79
Interest and investment income
2.80M
2.85M
2.97M
3.77M
Interest expense
-
-
-
-
Net interest expenses
2.80M
2.85M
2.97M
3.77M
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.88M
-21.92M
-51.92M
-62.37M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps